Hemostatic Effects of VELCADE Treatment in Multiple Myeloma Patients
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 08 Dec 2016 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 21 Jun 2016 Planned End Date changed from 1 Dec 2013 to 1 Jul 2017.
- 21 Jun 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017.